Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Metabolomic Discoveries GmbH. (12/12/11). "Press Release: New Service Platform for Sustainable and Competitive Biotechnological Processes. Insilico Biotechnology and Metabolomic Discoveries Have Agreed to Pool Their Expertise".

Organisations Organisation Metabolomic Discoveries GmbH
  Group Metabolon (Group)
  Organisation 2 Insilico Biotechnology AG
Products Product metabolomic services
  Product 2 software tools (bioinformatics)
Index term Index term Insilico Biotechnology–Metabolomic Discoveries: metabolomic services, 201112– collab product integration to provide services to industrial biotech
Persons Person Mauch, Klaus (Insilico Biotechnology 2004 became CEO before founder)
  Person 2 Schauer, Nicolas (Metabolomic Discoveries 201102 Managing Director)
     


Insilico Biotechnology and Metabolomic Discoveries have agreed to pool their expertise to provide industrial biotech customers with a more comprehensive package of high quality services.

The main focus of the cooperation lies in the field of applied systems biotechnology dealing with the metabolism of bacteria, fungi and mammalian cells. The combination of modern analytical methods with high-performance computing will give customers detailed insights into metabolism of cells. This will help shorten development times and form the basis for improving yields in biotechnological production processes.

On the novel service platform Insilico's proprietary databases, network models and software application tools will be combined synergistically with Metabolomic Discoveries' biochemical profiling platform to analyze metabolism. The latter company is based in Potsdam and employs state-of-the-art accurate mass analytical instruments in combination with biochemical expertise. This makes Metabolomic Discoveries a specialist in the analysis of metabolic processes.

"Metabolomic Discoveries' know-how will help us to validate mechanical metabolic models much faster since it focuses more directly on the specific aspect we investigate. The resulting models will then put us in the right direction for designing biotechnological processes which are more competitive and sustainable," states Klaus Mauch, Insilico's CEO. "We are delighted to have found such a suitable partner, both competent and reliable. Our expertise and tools complement each other beautifully so that we will be able to offer a wide portfolio of services at top levels. Customers can choose between overall service packages and individual customized schemes."

The companies' joint service platform will enable them to carry out metabolic simulations and analyses based on comprehensive metabolite measurements. This means that the collaborating scientists will be able to predict the effects of metabolic changes on aspects like cell growth and the identification of critical steps. Metabolomic Discoveries' CEO Nicolas Schauer is very pleased with the collaboration: "Insilico already leads the international field for modeling metabolic processes for biotech applications. The company knows all the large and small problems which can be encountered along metabolic engineering and is experienced in dealing with them accordingly. Teaming up puts us in the happy position of being able to offer our customers considerable advantages for optimizing existing bioprocesses or designing new ones."

Insilico Biotechnology reconstructs, simulates and predicts the performance of complex cellular systems for the chemical and pharmaceutical industries. Successful in business since 2001, Insilico has internationally renowned expertise and a unique technology platform for connecting cell model libraries with simulation processes. Insilico analyses the latest biotech data and integrates it in mechanistic whole-cell network models. With its high-performance computing techniques, Insilico develops superior solutions for manufacturing biochemicals and biopharmaceuticals and achieves considerable cuts in the time needed for drug toxicity tests. Insilico is a privately-owned company, located in Stuttgart, Germany.

   
Record changed: 2012-01-15

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Metabolon (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top